Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATRA
SELLAtara Biotherapeutics, Inc. · Healthcare · United States · $71M · Avg Vol: $627K/d
COMPANY DESCRIPTION
Atara Biotherapeutics, Inc. is a pioneer in allogeneic T-cell immunotherapy, developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. The company competitive moat is established by its proprietary Epstein-Barr virus T-cell platform, which enables the creation of off-the-shelf, targeted immunotherapies like Ebvallo. It operates as a leading clinical-stage biotechnology player at the forefront of cellular medicine.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 63.6M | 8.6M | 128.9M | 120.8M | 23.9% | 23.1M | 2.1M | 45.1M | -38.9% |
| EPS | -23.85 | -30.81 | -11.41 | 2.61 | — | -1.21 | -0.88 | 1.27 | -30.2% |
| Shares | 9.0M | 9.0M | 5.9M | 7.3M | -18.7% | 9.0M | — | — | — |
| Debt | 71.7M | 57.9M | 43.8M | 10.4M | -47.5% | 10.1M | — | — | — |
| Equity | 126.6M | -99.2M | -97.3M | -38.5M | — | — | — | — | — |
| Op CF | -270.4M | -193.0M | -68.7M | -50.9M | — | -25.9M | — | — | — |
| Inv CF | 203.0M | 123.9M | 8.6M | 18.1M | — | — | — | — | — |
| Fin CF | 53.1M | 2.0M | 59.3M | 16.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc.(you) | $71M | 29 | SELL |
| XBIT | XBiotech Inc. | $69M | 29 | SELL |
| LONA | LeonaBio, Inc. | $69M | 30 | SELL |
| PMVP | PMV Pharmaceuticals, Inc. | $66M | 25 | SELL |
| NRXS | NeurAxis, Inc. | $84M | 33 | SELL |
| ACET | Adicet Bio, Inc. | $73M | 21 | SELL |
| RLYB | Rallybio Corporation | $87M | 34 | SELL |
| PTHS | Pelthos Therapeutics Inc. | $90M | 24 | SELL |
| PLRX | Pliant Therapeutics, Inc. | $67M | 18 | STRONG SELL |
| SEER | Seer, Inc. | $108M | 34 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%